531661 Sigma-AldrichSMYD2 Inhibitor, AZ505 - CAS 1035227-43-0 - Calbiochem
AZ505 is a cell-permeable, potent, reversible inhibitor of SMYD2 (IC₅₀ = 120 nM, Ki = 300 nM) that binds to the peptide-binding groove of the enzyme.
More>> AZ505 is a cell-permeable, potent, reversible inhibitor of SMYD2 (IC₅₀ = 120 nM, Ki = 300 nM) that binds to the peptide-binding groove of the enzyme. Less<<Synonyms: N-Cyclohexyl-3-(3,4-dichlorophenethylamino)-N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)propanamide, HMTase Inhibitor XV
Recommended Products
Overview
| Replacement Information |
|---|
Key Spec Table
| CAS # | Empirical Formula |
|---|---|
| 1035227-43-0 | C₂₉H₃₈Cl₂N₄O₄ |
| References | |
|---|---|
| References | Ferguson, A.D., et al. 2011. Structure 19, 1262. |
| Product Information | |
|---|---|
| CAS number | 1035227-43-0 |
| Form | Off-white solid |
| Formulation | Supplied as a di-trifluoroacetate salt. |
| Hill Formula | C₂₉H₃₈Cl₂N₄O₄ |
| Chemical formula | C₂₉H₃₈Cl₂N₄O₄ |
| Reversible | Y |
| Quality Level | MQ100 |
| Applications |
|---|
| Biological Information | |
|---|---|
| Primary Target | SMYD2 |
| Purity | ≥95% by HPLC |
| Physicochemical Information | |
|---|---|
| Cell permeable | Y |
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Safety Information |
|---|
| Product Usage Statements |
|---|
| Packaging Information | |
|---|---|
| Packaged under inert gas | Packaged under inert gas |
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Catalogue Number | GTIN |
| 531661 | 0 |
Documentation
SMYD2 Inhibitor, AZ505 - CAS 1035227-43-0 - Calbiochem SDS
| Title |
|---|
References
| Reference overview |
|---|
| Ferguson, A.D., et al. 2011. Structure 19, 1262. |
Technical Info
| Title |
|---|
| Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System |
| White Paper: Further considerations of antibody validation and usage. |


